Search Results - "Hitron, Matthew"

Mass balance and pharmacokinetics of an oral dose of 14C‐napabucasin in healthy adult male subjects by Dai, Xiaoshu, Karol, Michael D., Hitron, Matthew, Hard, Marjie L., Blanchard, John Evan, Eraut, Nicola C. J. E., Rich, Natalie, Gufford, Brandon T.

“…This phase 1, open‐label study assessed14C‐napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites…”
Get full text

CTNI-45. A PHASE 1B/2 CLINICAL STUDY OF NAPABUCASIN IN COMBINATION WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH RECURRENT OR PROGRESSED GLIOBLASTOMA MULTIFORME (GBM) by Chi, Andrew, DeRobles, Paula, Foos, Emma, Hitron, Matthew, Mason, Warren

“…Abstract Napabucasin is an orally-administered NQO1–bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including…”
Get full text

Effect of food on exposure to napabucasin: Data from two phase I studies by Dai, Xiaoshu, Noda, Naoto, Xie, Yuran, Xu, Bo, Hitron, Matthew, Karol, Michael

“…Abstract only 477 Background: Napabucasin is an orally-administered NAD(P)H quinone dehydrogenase 1–bioactivatable investigational agent hypothesized to affect…”
Get full text

P38-8 Phase 1/2 study of menin inhibitor DSP-5336 in acute leukemia with and without MLL rearrangement or NPM1 mutation by Daver, Naval, Ikezoe, Takayuki, Watts, Justin, Hosono, Naoko, Ogawa, Yoshiaki, Miyazaki, Yasushi, Erba, Harry, Affinito, John, Cai, Hongliang, Brooks, Emily, Eguchi, Ken, Stoudemire, Jay, Watanabe, Akinobu, Kuwaki, Takahiro, Hitron, Matthew, Komarnitsky, Philip, Yuda, Junichiro

Get full text

Poster: AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation by Daver, Naval, Affinito, John, Cai, Hongliang, Dobrowolska, Hanna, Eguchi, Ken, Stoudemire, Jay, Watanabe, Akinobu, Hitron, Matthew

Get full text

AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation by Daver, Naval, Affinito, John, Cai, Hongliang, Dobrowolska, Hanna, Eguchi, Ken, Stoudemire, Jay, Watanabe, Akinobu, Hitron, Matthew

Get full text

Drug-drug interaction (DDI) potential of oral napabucasin in healthy adults by Dai, Xiaoshu, Karol, Michael D., Hitron, Matthew, Hard, Marjie, Goulet, Matthew T., Mclaughlin, Colleen F., Brantley, Scott J.

“…Abstract only 142 Background: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including…”
Get full text

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m) by Daver, Naval, Ikezoe, Takayuki, Watts, Justin, Hosono, Naoko, Ogawa, Yoshiaki, Miyazaki, Yasushi, Erba, Harry P., Affinito, John, Brooks, Emily, Eguchi, Ken, Cai, Hongliang, Xu, Bo, Stoudemire, Jay, Hitron, Matthew, Watanabe, Akinobu, Komarnitsky, Philip, Yuda, Junichiro

Get full text

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia by Daver, Naval, Zeidner, Joshua F., Yuda, Junichiro, Watts, Justin M., Levis, Mark J., Fukushima, Kentaro, Ikezoe, Takayuki, Ogawa, Yoshiaki, Brandwein, Joseph, Wang, Eunice S., Miyazaki, Yasushi, Pardee, Timothy, Hosono, Naoko, Shima, Takahiro, Yokoyama, Hisayuki, Asada, Noboru, Jurcic, Joseph, Cai, Hongliang, Watanabe, Akinobu, Hitron, Matthew, Brooks, Emily, Xu, Bo, Shah, Jatin, Kantarjian, Hagop M., Erba, Harry P.

“…Introduction: Menin inhibitors are an exciting new class of agents in development for patients (pts) with acute leukemia who overexpress HOXA9 and MEIS1 genes…”
Get full text

Abstract A113: Mass balance and pharmacokinetics of an oral dose of 14C-napabucasin in healthy adult male subjects by Dai, Xiaoshu, Karol, Michael D, Hitron, Matthew, Hard, Marjie, Blanchard, J Evan, Eraut, Nicola, Rich, Natalie, Gufford, Brandon

“…Abstract Introduction: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including pSTAT3…”
Get full text

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM) by Goldlust, Samuel Aaron, Chang, Jong Hee, Narita, Yoshitaka, Welch, Mary Roberta, Green, Richard M., Drappatz, Jan, Piccioni, David Eric, Kim, Yu Jung, Melear, Jason M., Tanaka, Shota, Wei, Kuo-Chen, Fink, Karen L., Pitz, Marshall W., Cloughesy, Timothy Francis, de Groot, John Frederick, McClellan, Nanci, Hitron, Matthew, Xu, Bo, Jin, Bo, Lebedinsky, Claudia

“…2022 Background: ODE is an investigational cancer vaccine derived from Wilms tumor 1. WIZARD was a randomized, adaptive, phase 3 study to test ODE + bev vs bev…”
Get full text

Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs) by Brooks, Emily, Lebedinsky, Claudia, Bekaii-Saab, Tanios S., Shah, Manish A., Jonker, Derek J., Kuchimanchi, Kamesh, Wybieralska, Ewa, Fontaine, Marilyn, Oh, Cindy, Sari, Suha, Foos, Emma, Xu, Bo, Hitron, Matthew

“…Abstract only 4147 Background: Retrospective studies of phosphorylated STAT3 (pSTAT3, a regulator of gene expression) in cancer-lineage cells have suggested it…”
Get full text

A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma by Kalra, Maitri, Cote, Gregory Michael, Heist, Rebecca Suk, Spittler, Aaron John, Yu, Song, Hitron, Matthew, Loehrer, Patrick J.

“…Abstract only…”
Get full text

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study by Shah, Manish A., Yoshino, Takayuki, Tebbutt, Niall C., Grothey, Axel, Tabernero, Josep, Xu, Rui-Hua, Cervantes, Andres, Oh, Sang Cheul, Yamaguchi, Kensei, Fakih, Marwan, Falcone, Alfredo, Wu, Christina, Chiu, Vi K., Tomasek, Jiri, Bendell, Johanna, Fontaine, Marilyn, Hitron, Matthew, Xu, Bo, Taieb, Julien, Van Cutsem, Eric

“…Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone…”
Get full text

A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma by Hitron, Matthew, Spittler, Aaron John, Cote, Gregory Michael, Heist, Rebecca Suk, Kossler, Kimiko, Li, Wei, Li, Youzhi, Li, Chiang, Loehrer, Patrick J.

“…Abstract only e20001 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene…”
Get full text

A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer by Edenfield, William Jeffery, Becerra, Carlos, Langleben, Adrian, Spira, Alexander I., Braiteh, Fadi S., Kossler, Kimiko, Gao, Yuan, Li, Youzhi, Hitron, Matthew, Li, Chiang

“…Abstract only 1084 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription…”
Get full text

BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM) by Mason, Warren P., de Robles, Paula, Borodyansky, Laura, Hitron, Matthew, Ortuzar, Waldo Feliu, Khan, Waheed, Xu, Bo, Li, Wei, Li, Youzhi, Li, C J

“…Abstract only e13525 Background: Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by targeting…”
Get full text

A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma by Cote, Gregory Michael, Edenfield, William Jeffery, Laurie, Scott Andrew, Chau, Nicole Grace, Becerra, Carlos, Spira, Alexander I., Li, Youzhi, Li, Wei, Hitron, Matthew, Li, Chiang

“…Abstract only 6036 Background: Amcasertib (BBI-503) is an oral first-in-class cancer stemness kinase inhibitor. By targeting multiple serine-threonine stemness…”
Get full text

A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer by Becerra, Carlos, Hanna, Wahid Tewfik, Richey, Stephen Lane, Cote, Gregory Michael, Laurie, Scott Andrew, Langleben, Adrian, Gao, Yuan, Li, Wei, Li, Youzhi, Hitron, Matthew, Li, Chiang

“…Abstract only 9052 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription…”
Get full text

A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma by Edenfield, William Jeffery, Becerra, Carlos, Braiteh, Fadi S., Spira, Alexander I., Sullivan, Ryan J., Panella, Timothy J., Li, Wei, Huang, Janet, Li, Youzhi, Flaherty, Keith, Hitron, Matthew, Li, Chiang

“…Abstract only 9553 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription…”
Get full text